These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 24812389)

  • 1. AIDS/HIV. Host controls of HIV neutralizing antibodies.
    Haynes BF; Verkoczy L
    Science; 2014 May; 344(6184):588-9. PubMed ID: 24812389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. INFECTIOUS DISEASES. Designer proteins produce potent HIV defense.
    Cohen J
    Science; 2015 Jun; 348(6241):1297. PubMed ID: 26089490
    [No Abstract]   [Full Text] [Related]  

  • 3. AIDS/HIV. A boost for HIV vaccine design.
    Burton DR; Weiss RA
    Science; 2010 Aug; 329(5993):770-3. PubMed ID: 20705840
    [No Abstract]   [Full Text] [Related]  

  • 4. Progress in HIV vaccine development.
    Hsu DC; O'Connell RJ
    Hum Vaccin Immunother; 2017 May; 13(5):1018-1030. PubMed ID: 28281871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages.
    Moody MA; Yates NL; Amos JD; Drinker MS; Eudailey JA; Gurley TC; Marshall DJ; Whitesides JF; Chen X; Foulger A; Yu JS; Zhang R; Meyerhoff RR; Parks R; Scull JC; Wang L; Vandergrift NA; Pickeral J; Pollara J; Kelsoe G; Alam SM; Ferrari G; Montefiori DC; Voss G; Liao HX; Tomaras GD; Haynes BF
    J Virol; 2012 Jul; 86(14):7496-507. PubMed ID: 22553329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design.
    Bonsignori M; Montefiori DC; Wu X; Chen X; Hwang KK; Tsao CY; Kozink DM; Parks RJ; Tomaras GD; Crump JA; Kapiga SH; Sam NE; Kwong PD; Kepler TB; Liao HX; Mascola JR; Haynes BF
    J Virol; 2012 Apr; 86(8):4688-92. PubMed ID: 22301150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV. The modern era of HIV-1 vaccine development.
    Mascola JR
    Science; 2015 Jul; 349(6244):139-40. PubMed ID: 26160931
    [No Abstract]   [Full Text] [Related]  

  • 8. HIV-1MN recombinant gp120 vaccine serum, which fails to neutralize primary isolates of HIV-1, does not antagonize neutralization by antibodies from infected individuals.
    Wrin T; Nunberg JH
    AIDS; 1994 Nov; 8(11):1622-3. PubMed ID: 7848602
    [No Abstract]   [Full Text] [Related]  

  • 9. Antibodies in HIV-1 vaccine development and therapy.
    Klein F; Mouquet H; Dosenovic P; Scheid JF; Scharf L; Nussenzweig MC
    Science; 2013 Sep; 341(6151):1199-204. PubMed ID: 24031012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen.
    Jardine JG; Ota T; Sok D; Pauthner M; Kulp DW; Kalyuzhniy O; Skog PD; Thinnes TC; Bhullar D; Briney B; Menis S; Jones M; Kubitz M; Spencer S; Adachi Y; Burton DR; Schief WR; Nemazee D
    Science; 2015 Jul; 349(6244):156-61. PubMed ID: 26089355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
    Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
    J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dancing with an escape artist.
    Deweerdt S
    Nature; 2010 Jul; 466(7304):S6-7. PubMed ID: 20631705
    [No Abstract]   [Full Text] [Related]  

  • 13. Tiny steps towards an HIV vaccine.
    Willyard C
    Nature; 2010 Jul; 466(7304):S8. PubMed ID: 20631706
    [No Abstract]   [Full Text] [Related]  

  • 14. Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier.
    Bonsignori M; Scott E; Wiehe K; Easterhoff D; Alam SM; Hwang KK; Cooper M; Xia SM; Zhang R; Montefiori DC; Henderson R; Nie X; Kelsoe G; Moody MA; Chen X; Joyce MG; Kwong PD; Connors M; Mascola JR; McGuire AT; Stamatatos L; Medina-Ramírez M; Sanders RW; Saunders KO; Kepler TB; Haynes BF
    Immunity; 2018 Dec; 49(6):1162-1174.e8. PubMed ID: 30552024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure of an N276-Dependent HIV-1 Neutralizing Antibody Targeting a Rare V5 Glycan Hole Adjacent to the CD4 Binding Site.
    Wibmer CK; Gorman J; Anthony CS; Mkhize NN; Druz A; York T; Schmidt SD; Labuschagne P; Louder MK; Bailer RT; Abdool Karim SS; Mascola JR; Williamson C; Moore PL; Kwong PD; Morris L
    J Virol; 2016 Nov; 90(22):10220-10235. PubMed ID: 27581986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus.
    Liao HX; Lynch R; Zhou T; Gao F; Alam SM; Boyd SD; Fire AZ; Roskin KM; Schramm CA; Zhang Z; Zhu J; Shapiro L; ; Mullikin JC; Gnanakaran S; Hraber P; Wiehe K; Kelsoe G; Yang G; Xia SM; Montefiori DC; Parks R; Lloyd KE; Scearce RM; Soderberg KA; Cohen M; Kamanga G; Louder MK; Tran LM; Chen Y; Cai F; Chen S; Moquin S; Du X; Joyce MG; Srivatsan S; Zhang B; Zheng A; Shaw GM; Hahn BH; Kepler TB; Korber BT; Kwong PD; Mascola JR; Haynes BF
    Nature; 2013 Apr; 496(7446):469-76. PubMed ID: 23552890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies.
    Ahmed Y; Tian M; Gao Y
    AIDS Res Ther; 2017 Sep; 14(1):50. PubMed ID: 28893278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mouse marginal zone B cells harbor specificities similar to human broadly neutralizing HIV antibodies.
    Pujanauski LM; Janoff EN; McCarter MD; Pelanda R; Torres RM
    Proc Natl Acad Sci U S A; 2013 Jan; 110(4):1422-7. PubMed ID: 23288906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses.
    Beltran-Pavez C; Bontjer I; Gonzalez N; Pernas M; Merino-Mansilla A; Olvera A; Miro JM; Brander C; Alcami J; Sanders RW; Sanchez-Merino V; Yuste E
    J Virol; 2022 Jan; 96(1):e0134321. PubMed ID: 34668778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poly- and autoreactivity of HIV-1 bNAbs: implications for vaccine design.
    Finney J; Kelsoe G
    Retrovirology; 2018 Jul; 15(1):53. PubMed ID: 30055635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.